Dexa Medica

Focus: Dexa Medica is an Indonesia-based biotechnology company focused on small molecule development across metabolic, neurological, women's health, respiratory, and oncology indications. The company operates primarily within the Southeast Asian market with a diversified pipeline spanning multiple therapeutic areas.

Metabolic Diseases Neurology Women's Health Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Dexa Medica

AI assessmentNot Hiring

No open roles listed right now. Follow Dexa Medica to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

14 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Striatin

Malnourished Children

N/A

Clinical Trials (1)

NCT06933862Effects of Channa Striata Extract on Intestinal Inflammation and Nutritional Status in Malnutritional Toddlers After Albendazole Therapy in South Bangka District

N/A

Help build intelligence for Dexa Medica

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active pipeline with 20 ongoing trials across Phase 1-3, including 8 Phase 3 programs offering near-term development milestones and regulatory catalysts.
Therapeutic diversity across metabolic diseases, neurology, women's health, respiratory, and oncology provides cross-functional learning opportunities.
Small molecule focus aligns with established medicinal chemistry and pharmacology expertise within a growing Asian biotech ecosystem.

Watch Out For

Zero active job openings indicate either full staffing, hiring freeze, or minimal growth trajectory—limiting entry and advancement opportunities.
Missing financial data (revenue, funding, cash position) raises questions about company stability, capitalization, and ability to fund pipeline progression through Phase 3/NDA.

Generated by Claude from Dexa Medica's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Dapagliflozin 10 mg film-coated tablet

Healthy

N/A

Clinical Trials (1)

NCT06127212Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets

N/A

Etoricoxib 120Mg Film-coated Tablet

Healthy

N/A

Clinical Trials (1)

NCT03422575Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

N/A

500 mg metformin hydrochloride extended release caplet

Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose

N/A

Clinical Trials (1)

NCT01677260Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet

N/A

Valsartan 160 mg film-coated caplets

Healthy

N/A

Clinical Trials (1)

NCT02518451Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg

N/A

DLBS1033

Healthy

N/A

Clinical Trials (1)

NCT01378585Safety and Efficacy of DLBS1033 in Healthy Subjects

N/A

Perindopril 4 mg tablets of PT Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT01682577Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

N/A

Pramipexole Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT02660060Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg

N/A

Lisinopril 10 mg tablets of PT Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT01936012Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition

N/A

Group I

Glimepiride BE Study in Healthy Volunteers Under Fasting Condition

N/A

Clinical Trials (1)

NCT01677247Bioequivalence Study of 4 mg Glimepiride Tablet

N/A

Pregabalin capsules 150 mg of Dexa Medica

Healthy

N/A

Clinical Trials (1)

NCT02233777Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg

N/A

Rivaroxaban 20 mg film-coated tablet

Healthy

Phase 1

Clinical Trials (1)

NCT06558045Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets

Phase 1

Tamsulosin 0.4 mg Sustained Release Tablet

Healthy

Phase 1

Clinical Trials (1)

NCT06558032Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets

Phase 1

Rivaroxaban 10 mg film-coated tablet

Healthy

Phase 1

Clinical Trials (1)

NCT06558058Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets

Phase 1

Apixaban 5 mg Film-Coated Tablet

Health

Phase 1

Clinical Trials (1)

NCT06817811Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet

Phase 1

DLBS2411

Gastric pH Regulation in Healthy Volunteers

Phase 1/2

Clinical Trials (1)

NCT01573403Efficacy and Safety of DLBS2411 in Healthy Volunteers

Phase 1/2

DLBS1033

Healthy Condition

Phase 1/2

Clinical Trials (1)

NCT01905878Biological Half Life of DLBS1033 in Healthy Volunteers

Phase 1/2

DLBS1033

Healthy

Phase 2

Clinical Trials (1)

NCT01694537The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

Phase 2

DLBS-32

Diabetes Mellitus, Type 2

Phase 2

Clinical Trials (1)

NCT01005069Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus

Phase 2

DLBS1425

Breast Cancer

Phase 2

Clinical Trials (1)

NCT01006785Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer

Phase 2

Proliverenol

Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase 2

Clinical Trials (1)

NCT06127225Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)

Phase 2

Predimenol tablet

Headache

Phase 2

Clinical Trials (1)

NCT06558006Safety and Efficacy Predimenol for Headache

Phase 2

Reconyl

Cough

Phase 2

Clinical Trials (1)

NCT06510257Safety and Efficacy Reconyl for Cough With/Without Sore Throat

Phase 2

Silfamin

Common Cold

Phase 2

Clinical Trials (1)

NCT06497439Efficacy and Safety of Silfamin for Common Cold

Phase 2

DLBS1033

Acute Non-ST Elevation Myocardial Infarction

Phase 2/3

Clinical Trials (1)

NCT02146664DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Phase 2/3

DLBS1033

Acute Ischemic Stroke

Phase 2/3

Clinical Trials (1)

NCT02133521DLBS1033 for Acute Ischemic Stroke Patients

Phase 2/3

DLBS1033

Diabetic Polyneuropathy

Phase 2/3

Clinical Trials (1)

NCT07475065The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

Phase 2/3

DLBS1442 100

Endometrioma

Phase 2/3

Clinical Trials (1)

NCT01942122DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

Phase 2/3

DLBS1425

Breast Cancer

Phase 2/3

Clinical Trials (1)

NCT01433562Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

Phase 2/3

DLBS1033

Diabetes

Phase 2/3

Clinical Trials (1)

NCT02145988DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

Phase 2/3

DLBS1449

Diabetic Patients

Phase 2/3

Clinical Trials (1)

NCT01972477DLBS1449 in Diabetic Patients With Low HDL

Phase 2/3

DLBS1033

ST Elevation Myocardial Infarction

Phase 2/3

Clinical Trials (1)

NCT02976701Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Phase 2/3

Placebo

Acute Ischemic Stroke

Phase 3

Clinical Trials (1)

NCT02362984DLBS1033 for the Treatment of Acute Ischemic Stroke

Phase 3

DLBS1033

Acute Ischemic Stroke

Phase 3

Clinical Trials (1)

NCT01790997Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Phase 3

DLBS3233

Type-2 Diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT01472614Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

Phase 3

Reconyl

Cough

Phase 3

Clinical Trials (1)

NCT07420491The Efficacy and Safety of Reconyl in Acute Cough Treatment

Phase 3

Galatonol 300 mg/Striatin 30 mg

Lactation Induced

Phase 3

Clinical Trials (1)

NCT06558071Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers

Phase 3

Placebo caplet of DLBS2411

Functional Dyspepsia

Phase 3

Clinical Trials (1)

NCT05248802DLBS2411 Treatment For Functional Dyspepsia

Phase 3

DLBS3233

Polycystic Ovary Syndrome (PCOS)

Phase 3

Clinical Trials (1)

NCT01733459Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Phase 3

Triptorelin Embonate

Endometriosis

Phase 3

Clinical Trials (1)

NCT06525155Effect GnRH Agonist Administration in Endometriosis Cyst Patients

Phase 3

DLBS3233

Polycystic Ovary Syndrome (PCOS)

Phase 3

Clinical Trials (1)

NCT01999686PCOS Treatment Using DLBS3233, Metformin, and Combination of Both

Phase 3

Omeprazole

Gastroesophageal Reflux Disease (GERD)

Phase 3

Clinical Trials (1)

NCT03367195Efficacy and Safety of DLBS2411 in the Management of GERD

Phase 3

DLBS3233

Prediabetic

Phase 3

Clinical Trials (1)

NCT01531933Efficacy and Safety of DLBS3233 in Prediabetic Patients

Phase 3

Omeprazole

Non-Bleeding Peptic Ulcers

Phase 3

Clinical Trials (1)

NCT02262169DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers

Phase 3

Striatin

Severe Acute Malnutrition

Phase 3

Clinical Trials (1)

NCT07089329Efficacy of Striatin in Malnourished Children

Phase 3

Placebo of DLBS3233

Type-2-diabetes Mellitus

Phase 3

Clinical Trials (1)

NCT01645332Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus

Phase 3

DLBS5055 200mg

Male Infertility

Phase 4

Clinical Trials (1)

NCT06100432Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ β-carotene) for Infertile Males

Phase 4

DLBS1033

Type 2 Diabetes Mellitus

Phase 4

Clinical Trials (1)

NCT01865474Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Phase 4

DLBS1033

Benign Paroxysmal Positional Vertigo (Disorder)

Phase 4

Clinical Trials (1)

NCT07075289Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 49 clinical trials

Top TAs: Metabolic Diseases, Neurology, Women's Health

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

7 pipeline

4 pipeline

3 pipeline

2 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline